<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00550797</url>
  </required_header>
  <id_info>
    <org_study_id>TPI ASM8-205</org_study_id>
    <nct_id>NCT00550797</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy TPI ASM8 in Subjects With Asthma</brief_title>
  <official_title>A Multi-center, Double-blind, Randomized, Placebo-controlled, Crossover Study to Evaluate the Safety and Efficacy of 14-day Inhaled TPI ASM8 in Subjects With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmaxis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>i3 Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pharmaxis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The researchers propose to study the airways of asthmatics given TPI ASM8 for 14 days, and
      examine the protective effects on allergen-induced bronchoconstriction, hyperresponsiveness
      and airway inflammation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Early and late asthmatic responses were attenuated by ASM8 and by placebo
      solution.Methacholine challenge was not affected by study medication. Other parameters were
      unchanged.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and allergen-induced maximum decrease in FEV1 for Late Asthmatic Response</measure>
    <time_frame>Safety (Trial duration) + LAR (Day 14)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exploratory Endpoints only: EAR on Day 14, AMP-induced airway hyperresponsiveness on Day 10,eNO on Day 14, PK/PD in sputum and plasma</measure>
    <time_frame>study duration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Allergic Asthma</condition>
  <arm_group>
    <arm_group_label>No.1 ASM8 (oligonucleotide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TPI ASM8 1mg/mL in phosphate buffered saline (PBS) solution; 1 mg will be administered daily (morning) by inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phosphate Buffer solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo solution (PBS) will be administered daily in the form of 1 mL of PBS (phosphate buffered saline) by inhalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TPI ASM8</intervention_name>
    <description>Administered with the I-Neb device from Respironics once daily by inhalation over 2 treatment periods of 14 days each</description>
    <arm_group_label>No.1 ASM8 (oligonucleotide)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Administered with the I-Neb device from Respironics once daily by inhalation over 2 treatment periods of 14 days each</description>
    <arm_group_label>Phosphate Buffer solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women 18 to 65 years of age

          -  Intermittent mild to moderate allergic asthma as defined by ATS/ERS criteria

          -  History of episodic wheeze and shortness of breath

        Exclusion Criteria:

          -  Significant acute or chronic medical, neurologic, cardiovascular or psychiatric
             illness, asthma exacerbation or respiratory infection in the preceding 6 weeks

          -  Use of oral/injectable corticosteroids within the last 60 days or currently on any
             anti-asthmatic drugs, immunosuppressives, nonsteroidal anti-inflammatory drugs or
             anticoagulants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian O'Connor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kings College Hospital, London, United Kingdom</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rene Pageau, M.Sc.Pharm</last_name>
    <role>Study Director</role>
    <affiliation>Topigen Pharmaceuticals, Montreal, Quebec/Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierluigi Paggiaro, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pisa, Pisa, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dave Singh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Evaluation Unit, Manchester, UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter J. Sterk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Amsterdam, Amsterdam, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Piero Maestrelli, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Padova, Padova, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>King's College inLondon</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2007</study_first_submitted>
  <study_first_submitted_qc>October 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2007</study_first_posted>
  <last_update_submitted>November 18, 2013</last_update_submitted>
  <last_update_submitted_qc>November 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Steroid-naive, non-smokers</keyword>
  <keyword>Mild to moderate allergic asthmatic adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

